Is the Co-administration of Metformin and Clomiphene Superior to Induce Ovulation in Infertile Patients With Poly Cystic Ovary Syndrome and Confirmed Insulin-Resistance: A Double Blind Randomized Clinical Trial.
Clomiphene Citrate
Infertility
Insulin Resistance
Metformin
Poly Cystic Ovary Syndrome
Journal
Journal of family & reproductive health
ISSN: 1735-8949
Titre abrégé: J Family Reprod Health
Pays: Iran
ID NLM: 101496684
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
This study aimed to compare the effects of clomiphene citrate (CC) combined with metformin or placebo on infertile patients with poly cystic ovary syndrome (PCOS) and insulin resistance (IR). We included 151 infertile women with PCOS and IR in a university hospital from November 2015 to April 2022 in this prospective, double-blind, randomized, placebo-controlled trial. Patients were randomized into two groups; group A: received CC plus metformin (n = 76) and group B: received CC plus placebo (n = 75). The ovulation rate was the main outcome measure. Clinical pregnancy, ongoing pregnancy, live birth and abortion rates were secondary outcome measures. There was no remarkable difference in ovulation rate in two groups. Moreover, no significant changes were observed in clinical pregnancy, ongoing pregnancy, live birth and abortion rates between two groups. A larger proportion of women in group A suffered from side effects of metformin (9.3% versus 1.4%; p=0.064), although this was not significant. In IR infertile women with PCOS, metformin pre-treatment did not increase the ovulation, clinical pregnancy and live birth rates in patients on clomiphene citrate.
Identifiants
pubmed: 37538230
doi: 10.18502/jfrh.v17i1.11973
pii: JFRH-17-21
pmc: PMC10394487
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21-28Informations de copyright
Copyright © 2023 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences.
Déclaration de conflit d'intérêts
Conflict of Interests Authors declare no conflict of interests.
Références
Hum Reprod Update. 2007 Nov-Dec;13(6):527-37
pubmed: 17767003
N Engl J Med. 1998 Jun 25;338(26):1876-80
pubmed: 9637806
Minerva Ginecol. 2014 Jun;66(3):299-301
pubmed: 24971785
Fertil Steril. 2004 Jan;81(1):19-25
pubmed: 14711538
BMJ. 2006 Jun 24;332(7556):1485
pubmed: 16769748
Clin Endocrinol (Oxf). 2011 Nov;75(5):692-7
pubmed: 21592169
Hum Reprod. 2010 Feb;25(2):544-51
pubmed: 19910321
N Engl J Med. 2007 Feb 8;356(6):551-66
pubmed: 17287476
J Clin Endocrinol Metab. 2010 Dec;95(12):5305-13
pubmed: 20826578
Fertil Steril. 1999 Feb;71(2):323-7
pubmed: 9988406
Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S135-48
pubmed: 11460565
J Clin Endocrinol Metab. 1997 Dec;82(12):4075-9
pubmed: 9398716
J Obstet Gynaecol Can. 2006 Jul;28(7):595-599
pubmed: 16916482
Fertil Steril. 2002 Jan;77(1):101-6
pubmed: 11779598
Aust N Z J Obstet Gynaecol. 2011 Apr;51(2):125-9
pubmed: 21466513
Hum Reprod Update. 2010 May-Jun;16(3):231-45
pubmed: 19934213
Cochrane Database Syst Rev. 2019 Dec 17;12:CD013505
pubmed: 31845767
Fertil Steril. 1979 Dec;32(6):641-5
pubmed: 510566
Fertil Steril. 1996 May;65(5):946-9
pubmed: 8612854
Ther Adv Reprod Health. 2020 May 22;14:2633494120908818
pubmed: 32518914
Ann Agric Environ Med. 2013;20(3):528-32
pubmed: 24069859
Fertil Steril. 2010 Dec;94(7):2659-64
pubmed: 20451181
Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):214-20
pubmed: 15063963
Hum Reprod. 2001 Aug;16(8):1625-31
pubmed: 11473953
Eur Rev Med Pharmacol Sci. 2020 Aug;24(15):8136-8142
pubmed: 32767342
J Clin Endocrinol Metab. 2012 May;97(5):1492-500
pubmed: 22419702
N Engl J Med. 1995 Sep 28;333(13):853-61
pubmed: 7651477
Fertil Steril. 2017 Sep;108(3):426-441
pubmed: 28865539